Kyntra Bio (KYNB) Receivables - Net (2014 - 2026)
Kyntra Bio (KYNB) posted Receivables - Net of $5.0 million for Q1 2026, up 2233.33% sequentially from $216000.0 in Q4 2025, and up 3328.57% YoY from $147000.0 in Q1 2025.
Kyntra Bio (KYNB) Receivables - Net (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Receivables - Net for 13 years, with the latest figure at $5.0 million in Q1 2026.
- Quarterly Receivables - Net rose 3328.57% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 3328.57% YoY) and the FY2025 annual result came in at $5.5 million, up 1043.45% from the prior year.
- Receivables - Net climbed to $5.0 million in Q1 2026 per KYNB's latest filing, from $216000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $49.2 million in Q1 2022 and troughed at $136000.0 in Q2 2025.
- A 5-year average of $18.3 million and a median of $15.3 million in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2025 and 2026: Receivables - Net slumped 99.6% in 2025, then jumped 3328.57% in 2026.
- Over 5 years, Receivables - Net stood at $49.2 million in 2022, then plunged by 89.59% to $5.1 million in 2023, then slumped by 90.61% to $481000.0 in 2024, then plunged by 55.09% to $216000.0 in 2025, then jumped by 2233.33% to $5.0 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $5.0 million, $216000.0, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 347,000.00 |
| Jun 30, 2026 | 347,000.00 |
| Mar 31, 2026 | 5.04 Mn |
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 216,000.00 |
| Dec 31, 2025 | 216,000.00 |
| Sep 30, 2025 | 5.50 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 481,000.00 |
| Dec 31, 2024 | 481,000.00 |
| Sep 30, 2024 | 29.03 Mn |
| Sep 30, 2024 | 29.03 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Mar 31, 2024 | 37.08 Mn |
| Mar 31, 2024 | 37.08 Mn |